Last reviewed · How we verify

NCT06301009: AI-CAC-PVS

The AI-CAC Model for Subclinical Atherosclerosis Detection on Chest X-ray

Status unknown NA Last updated 8 March 2024
What this trial tests

NA trial testing AI-CAC score in Cardiovascular Diseases in 500 participants. Status unknown.

Timeline
1 April 2024
Primary endpoint
1 October 2025
1 October 2025

Quick facts

Lead sponsorA.O.U. Città della Salute e della Scienza
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment500
Start date1 April 2024
Primary completion1 October 2025
Estimated completion1 October 2025

Drugs / interventions tested

Conditions studied

Sponsor

A.O.U. Città della Salute e della Scienza — full company profile →

Who can join

Adults 40 to 75, any sex, with Cardiovascular Diseases or Atherosclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The AI-CAC model is an artificial intelligence system capable of assessing the presence of subclinical atherosclerosis on a simple chest radiograph. The present study will provide prospective validation of its diagnostic performance in a primary prevention population with a clinical indication for coronary artery calcium (CAC) testing.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cardiovascular Diseases

Currently open trials in the same condition.

Other A.O.U. Città della Salute e della Scienza trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06301009.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing